These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12476650)

  • 1. Initial experience with paclitaxel-coated stents.
    Grube E; Büllesfeld L
    J Interv Cardiol; 2002 Dec; 15(6):471-5. PubMed ID: 12476650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug eluting stents: initial experiences.
    Grube E; Gerckens U; Müller R; Büllesfeld L
    Z Kardiol; 2002; 91 Suppl 3():44-8. PubMed ID: 12641014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting stents: clinical experiences and perspectives.
    Grube E; Gerckens U; Buellesfeld L
    Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel-eluting stents: current clinical experience.
    Grube E; Buellesfeld L
    Am J Cardiovasc Drugs; 2004; 4(6):355-60. PubMed ID: 15554720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [When are drug-eluting stents effective? A critical analysis of the presently available data].
    Silber S
    Z Kardiol; 2004 Sep; 93(9):649-63. PubMed ID: 15365732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug-eluting stents do they make the difference? ].
    Presbitero P; Asioli M
    Minerva Cardioangiol; 2002 Oct; 50(5):431-42. PubMed ID: 12384625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [State of treatment of coronary artery disease by drug releasing stents].
    Müller R; Büllesfeld L; Gerckens U; Grube E
    Herz; 2002 Sep; 27(6):508-13. PubMed ID: 12378395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.
    Büllesfeld L; Gerckens U; Müller R; Grube E
    Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients.
    Silber S
    J Interv Cardiol; 2003 Dec; 16(6):485-90. PubMed ID: 14632945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis.
    Doggrell SA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2209-20. PubMed ID: 15500367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives of drug-eluting stents: the next revolution.
    Moses JW; Kipshidze N; Leon MB
    Am J Cardiovasc Drugs; 2002; 2(3):163-72. PubMed ID: 14727979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
    Silber S
    J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.
    Grube E; Silber S; Hauptmann KE; Mueller R; Buellesfeld L; Gerckens U; Russell ME
    Circulation; 2003 Jan; 107(1):38-42. PubMed ID: 12515740
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.